CBS Sunday Morning

Age and Longevity

The video frames aging not as an immutable fate but as a biomedical target, spotlighting a new generation of researchers who argue that the aging process can be delayed, halted, or even reversed. It weaves together interviews with leading scientists, biotech entrepreneurs, and centenarians to illustrate how the field has moved from speculative fiction to a rapidly funded industry. Key insights include the repurposing of existing drugs such as metformin, which may curb cardiovascular disease, Alzheimer’s, and cancer, and the discovery of a soil‑derived compound, repamy, that extends mouse lifespan. Researchers like Harvard biologist David Sinclair and Dr. Neil Barzeli advocate treating aging itself as the root cause of age‑related diseases. Epigenetic clocks now let individuals submit a saliva sample and receive a biological‑age readout, a metric that can be shifted by diet, sleep, and exercise. Caloric restriction and intermittent fasting trigger hormetic stress responses—activating sirtuins and other longevity pathways—demonstrated to add 40% more life in animal studies. Illustrative examples range from blind mice regaining vision after cellular rejuvenation, to a 96‑year‑old marathoner who has avoided cancer and dementia, to extreme longevi­ty models such as naked mole‑rats, elephants with extra TP53 copies, and hydra that seemingly never age. The narrative also cites Cynthia Kenyon’s worm experiments, where a single gene tweak doubled lifespan, underscoring the power of genetic interventions. The implications are profound: billions of dollars are flowing into biotech startups aiming to commercialize anti‑aging therapies, promising to shift healthcare from treating individual diseases to extending healthspan. If successful, these advances could reshape pension systems, labor markets, and societal attitudes toward aging, turning what was once a terminal condition into a manageable, perhaps even reversible, aspect of human biology.